continued	continued
Institution	Institution
Mie University Hospital	Osaka City General Medical Center
Minoh City Hospital	Osaka City University Hospital
Mito Red Cross Hospital	Osaka Hospital of Japan Seafarers relief Association
Mitsui Memorial Hospital	Osaka Koseinenkin Hospital
Murakami General Hospital	Osaka Medical Center for Cancer and Cardiovascular Diseases
Musashimurayama Hospital	Osaka Medical College Hospital
Nagahama City Hospital	Osaka Prefectural Hospital Organization Osaka General Medical Center
Nagano Red Cross Hospital	Osaka Red Cross Hospital
Nagasaki University Hospital	Otsu Red Cross Hospital
Nagayoshi General Hospital	Ryukyu University Hospital
Nagoya City University Hospital	Saga University Hospital
Nagoya Daiichi Red Cross Hospital	Saiseikai General Hospital
Nagoya University Hospital	Saiseikai Kyoto Hospital
Nanpuh Hospital	Saiseikai Utsunomiya Hospital
Nara Medical University Hospital	Saitama City Hospital
National Cancer Center Hospital	Saitama Medical Center
National Defense Medical College Hospital	Saitama Medical Center Jichi Medical University
National Hospital Organization Chiba Medical Center	Saitama Medical University Hospital
National Hospital Organization Fukuoka-higashi Medical Center	Saitama Medical University International Medical Center
National Hospital Organization Hokkaido Cancer Center	Saitama Prefectural Cancer Center
National Hospital Organization Iwakuni Medical Center	Saitama Red Cross Hospital
National Hospital Organization Kure Medical Center	Saitama Social Insurance Hospital
National Hospital Organization Kyushu Cancer Center	Sakai Municipal Hospital
National Hospital Organization Matsumoto National Hospital	Saku Central Hospital
National Hospital Organization Nagoya Medical Center	Sanno Hospital
National Hospital Organization Osaka National Hospital	Sano Kousei General Hospital
National Hospital Organization Sendai Medical Center	Sato Clinic
National Hospital Organization Tokyo Medical Center	Sendai City Hospital
Nihon University Itabashi Hospital	Shiga Medical Center for Adults
Niigata Cancer Center Hospital	Shiga University of Medical Science Hospital
Niigata City General Hospital	Shikoku Cancer Center
Niigata Prefectural Shibata Hospital	Shimane University Hospital
Niigata University Medical and Dental Hospital	Shimizu Welfare Hospital
Nikko Memorial Hospital	Shinshiro Municipal Hospital
Nippon Medical School Chiba Hokusoh Hospital	Shinshu University Hospital
Nippon Medical School Hospital	Shizuoka Cancer Center
Nippon Medical School Musashi Kosugi Hospital	Shizuoka City Shimizu Hospital
Nippon Medical School Tama Nagayama Hospital	Shizuoka City Shizuoka Hospital
Nishi-Kobe Medical Center	Shizuoka General Hospital
Nishinomiya Municipal Central Hospital	Showa University Hospital
Nomura Medical Park Hospital	Showa University Northern Yokohama Hospital
NTT East Japan Kanto Hospital	Showa University Toyosu Hospital
Numazu City Hospital	Social Insurance Omuta Tenryo Hospital
Ohta General Hospital Foundation Ohta Nishinouchi Hospital	Social Insurance Tagawa Hospital
Oita Red Cross Hospital	Social Insurance Yokohama Central Hospital
Oita University Hospital	Sonoda Daiichi Hospital
Oizumi Gastrointestinal Medical Clinic	St. Luke's International Hospital
Okaziama Saisaikai Cananal Hasnital	Colle Collaboration and participation

Sugita Genpaku Memorial Obama Municipal Hospital

Suita Municipal Hospital

Takaoka Hospital



Okayama Saiseikai General Hospital

Okayama University Hospital

Onomichi Municipal Hospital

#### continued

## Institution

Takasago Municipal Hospital

Tenri Hospital

The Cancer Institute Hospital of JFCR

The Jikei University Hospital

Tochigi Cancer Center

Toho University Omori Medical Center

Toho University Sakura Medical Center

Tohoku Kosai Hospital

Tohoku University Hospital

Tokai University Hachioji Hospital

Tokai University Hospital

Tokushima Red Cross Hospital

Tokushima University Hospital

Tokyo Medical and Dental University Hospital

Tokyo Medical University Ibaraki Medical Center

Tokyo Medical University Hospital

Tokyo Metropolitan Cancer and Infectious Center Komagome Hospital

Tokyo Metropolitan Health and Medical

Corporation Toshima Hospital Tokyo University Hospital

Tokyo Women's Medical University Hospital

Tokyo Women's Medical University Medical Center East

Tonan Hospital

Toranomon Hospital

Tottori Prefectural Central Hospital

Tottori University Hospital

Toyama Prefectural Central Hospital

Toyama University Hospital

Tsuchiura Kyodo Hospital

Tsukuba University Hospital

University Hospital, Kyoto Prefectural

University of Medicine

University of Miyazaki Hospital

Yamagata Prefectural and Sakata Municipal Hospital Organization

Yamagata Prefectural Central Hospital

Yamagata Prefectural Shinjo Hospital

Yamagata University Hospital

Yamaguchi-ken Saiseikai Shimonoseki General Hospital

Yamaguchi University Hospital

Yamanashi Prefectural Central Hospital

Yamanashi University Hospital

Yao Municipal Hospital

Yatsu Hoken Hospital

Yokohama City Municipal Hospital

Yokohama City University Hospital

Yokohama City University Medical Center

Yuri General Hospital

## (Total 237 institutions)

## Patient background

Table 1 Age and gender

\*Excluding 40 missing cases of gender

Age	Male	Female	Unknown	Cas	es (%)
~29 .	8	1	0	9	(0.2%)
30~39	10	4	0	14	(0.3%)
40~49	123	25	0	148	(3.3%)
50~59	842	139	0	981	(21.9%)
60~69	1535	226	1	1762	(39.4%)
70~79	1168	154	3	1325	(29.6%)
80~89	179	44	0	223	(5.0%)
90~	10	4	0	14	(0.3%)
Total	3875	597	4	4476	
Missing	25	6	0	31	

Table 11 Types of primary treatment

Treatments		ses (%)
Surgery	2607	(57.7%)
Esophagectomy	2456	(54.3%)
Palliative	151	(3.3%)
Chemotherapy/Radiotherapy	1178	(26.1%)
Endoscopic treatment	477	(10.5%)
others	46	(1.0%)
None/Unknown	214	(4.7%)
Total	4522	
Missing	25	

Table 12 Tumor location

 $\ensuremath{^{*}}$  Excluding 293 treatment unknown, other, and missing cases of treatment types

Location of tumor	Cas	es (%)
Cervical	204	(4.8%)
Upper thoracic	570	(13.4%)
Middle thoracic	1993	(46.9%)
Lower thoracic	1178	(27.7%)
Abdominal	195	(4.6%)
EG	35	(0.8%)
EG-Junction(E=G)	28	(0.7%)
Cardia (G)	3	(0.1%)
Others	0	(0.0%)
Unknown	41	(1.0%)
Total	4247	
Missing	7	

Table 15 Histologic types of biopsy specimens

\* Excluding 285 treatment unknown, other, and missing cases of treatment types

Histologic types	Total (%)		
Not examined	39	(0.9%)	
SCC	3891	(91.4%)	
SCC	2360	(55.5%)	
Well diff.	345	(8.1%)	
Moderately diff.	882	(20.7%)	
Poorly diff.	304	(7.1%)	
Adenocarcinoma	155	(3.6%)	
Undifferentiated	20	(0.5%)	
Carcinosarcoma	13	(0.3%)	
Malignant melanoma	8	(0.2%)	
Other tumors	34	(0.8%)	
Dysplasia	0	(0.0%)	
Unknown	95	(2.2%)	
Total	4255		
Missing	7		

Table 16 Depth of tumor invasion, cT (UICC TNM 6th)

\* Excluding 285 treatment unknown, other, and missing cases of treatment types

cT	Total (%)		
cTX	16	(0.4%)	
сТ0	9	(0.2%)	
cTis	89	(2.1%)	
cT1	185	(4.4%)	
cT1a	420	(9.9%)	
cT1b	699	(16.4%)	
cT2	542	(12.7%)	
сТ3	1635	(38.5%)	
cT4	544	(12.8%)	
Unknown	112	(2.6%)	
Total	4252		
Missing	10		

Table 17 Lymph node metastasis, cN (UICC TNM 6th)

 $\ensuremath{^{*}}$  Excluding 285 treatment unknown, other, and missing cases of treatment types

cN	To	Total (%)		
cNX	65	(1.5%)		
cN0	1946	(45.8%)		
cN1	2115	(49.7%)		
Unknown	126	(3.0%)		
Total	4252			
Missing	10			

Table 18 Distant metastasis, cM (UICC TNM 6th)

\* Excluding 285 treatment unknown, other, and missing cases of treatment types

сМ	Total (%)		
cMX	35	(0.8%)	
сМ0	3530	(83.0%)	
cM1	152	(3.6%)	
cM1a	108	(2.5%)	
cM1b	333	(7.8%)	
Unknown	94	(2.2%)	
Total	4252		
Missing	10		

Table 20 Clinical stage (UICC TNM 6th)

\* Excluding 285 treatment unknown, other, and missing cases of treatment types

	End	oscopic	Chemotherapy and/or		Surgery					
cStage		atment (%)		erapy and/or erapy (%)		ive surgery (%)	Esophage	ctomy (%)	Tota	ıl (%)
0	66	(13.9%)	4	(0.3%)	2	(1.3%)	13	(0.5%)	85	(2.0%)
I	357	(75.0%)	146	(12.4%)	26	(17.3%)	574	(23.4%)	1103	(25.9%)
IIA	1	(0.2%)	131	(11.1%)	28	(18.7%)	465	(19.0%)	625	(14.7%)
IIB	5	(1.1%)	82	(7.0%)	13	(8.7%)	291	(11.9%)	391	(9.2%)
Ш	5	(1.1%)	398	(33.9%)	55	(36.7%)	797	(32.5%)	1255	(29.5%)
IV	2	(0.4%)	101	(8.6%)	4	(2.7%)	33	(1.3%)	140	(3.3%)
IVA	1	(0.2%)	51	(4.3%)	3	(2.0%)	52	(2.1%)	107	(2.5%)
IVB	4	(0.8%)	173	(14.7%)	7	(4.7%)	131	(5.3%)	315	(7.4%)
Unknown	35	(7.4%)	89	(7.6%)	12	(8.0%)	95	(3.9%)	231	(5.4%)
Total	476		1175		150		2451		4252	
Missing	1		3		ı		5		10	

## II. Clinical results of patients treated endoscopically in 2005

Table 22 Treatment details in patients receiving endoscopy

Treatment details	Cas	ses (%)
EMR	266	(55.9%)
EMR + YAG laser / APC	6	(1.3%)
EMR + ESD	1	(0.2%)
ESD	181	(38.0%)
ESD + other treatment	1	(0.2%)
PDT	1	(0.2%)
PDT + Esophageal stent	1	(0.2%)
YAG laser / APC	2	(0.4%)
Esophageal stent	14	(2.9%)
Tracheal stent	0	(0.0%)
Esophageal stenting + tracheal stenting	2	(0.4%)
Others	]	(0.2%)
Total	476	
Missing	1	

EMR: endoscopic mucosal resection, ESD: endoscopic submucosaldissection,

 $PDT: photodynamic\ the rapy,\ YAG:\ yttrium\ aluminum\ garnet,\ APC:\ Argon\ plasma\ coagulation,$ 

MCT: microwave coagulation theraphy, RFA: Radiofrequency ablation



 $<sup>\</sup>ast$  "Esophageal stenting + tracheal stenting + other (PEG)" case is included in "Esophageal stenting + tracheal stenting".


Table 26 Complications of EMR/ESD

Complications of EMR/ESD	Cas	ses (%)
None	428	(94.1%)
Perforation	9	(2.0%)
Bleeding	0	(0.0%)
Mediastinitis	0	(0.0%)
Stenosis	13	(2.9%)
Perforation+Mediastinitis	0	(0.0%)
Perforation+Stenosis	0	(0.0%)
Perforation+Mediastinitis+Stenosis	0	(0.0%)
Others	5	(1.1%)
Unknown	0	(0.0%)
Total	455	
Missing	1	

Table 30 Depth of tumor invasion of EMR/ESD specimens

Complications of EMR/ESD	Cas	Cases (%)	
None	428	(94.1%)	
Perforation	9	(2.0%)	
Bleeding	0	(0.0%)	
Mediastinitis	0	(0.0%)	
Stenosis	13	(2.9%)	
Perforation+Mediastinitis	0	(0.0%)	
Perforation+Stenosis	0	(0.0%)	
Perforation+Mediastinitis+Stenosis	0	(0.0%)	
Others	5	(1.1%)	
Unknown	0 (0.0%		
Total	455		
Missing	. 1		


Fig. 3 Survival of patients treated by EMR/ESD in relation to the pathological depth of tumor invasion (pT), pTis (n = 104) pT1a (n = 220) pT1b (n = 42)



	Years after EMR/ESD										
	1	2	3	4	5	6	7	8			
pTis	98.0%	94.1%	92.1%	89.1%	88.1%	84.7%	83.0%	83.0%			
pT1a	98.2%	94.4%	91.1%	86.7%	85.7%	84.3%	82.5%	82.5%			
pT1b	95.2%	92.8%	85.3%	80.2%	74.6%	74.6%	71.1%	71.1%			



Fig. 4 Survival of patients treated by EMR/ESD in relation to the lymphatic or venous invasion, Lymphatic and venous invasion (-) (n = 326), Lymphatic or venous invasion (+) (n = 28), Unknown (n = 21)



	Years after EMR/ESD									
	1	2	3	4	5	6	7	8		
Lymphatic and venous invasion (-)	98.8%	95.6%	92.2%	88.7%	86.9%	84.9%	83.1%	83.1%		
Lymphatic or venous invasion (+)	89.3%	78.1%	74.4%	63.2%	63.2%	63.2%	59.0%	59.0%		
Unknown	89.9%	89.9%	83.0%	83.0%	83.0%	83.0%	83.0%	83.0%		

# III. Clinical results in patients treated with chemotherapy and/or radiotherapy in 2005

Table 33 Dose of irradiation (non-surgically treated cases)


		Radiotl	nerapy								
Dose of irradiation (Gy)	Dose of irradiation (Gy) alone (%)		with chemotherapy (%)		Palliative (%)		Recurrence (%)		Others (%)	Total (%)	
0	0	(0.0%)	0	(0.0%)	0	(0.0%)	0	(0.0%)	0	0	(0.0%)
-29	3	(0.9%)	1	(1.4%)	9	(11.7%)	1	(7.7%)	0	14	(2.8%)
30-39	8	(2.4%)	1	(1.4%)	10	(13.0%)	0	(0.0%)	0	19	(3.8%)
40-49	13	(3.9%)	4	(5.6%)	5	(6.5%)	2	(15.4%)	0	24	(4.8%)
50-59	46	(13.7%)	5	(6.9%)	11	(14.3%)	3	(23.1%)	0	65	(13.1%)
60-69	261	(77.7%)	50	(69.4%)	32	(41.6%)	7	(53.8%)	0	350	(70.3%)
70-	5	(1.5%)	11	(15.3%)	10	(13.0%)	0	(0.0%)	0	26	(5.2%)
Total	336		72		77		13		0	498	
Median (min - max) 60 (1.8 - 70.2)		60	60 ( 22 - 70.2 )		60 (2 - 76.8)		20 - 67.6 )	-	60 ( 1.8 - 70.6 )		
Missing	5		0		8		0		1	14	



Table 34 Dose of irradiation (surgically treated cases)

Dose of irradiation (Gy)	Preop	ne RT (%)	Postope RT (%)			
0	0	(0.0%)	0	(0.0%)		
-29	3	(1.6%)	1	(1.6%)		
30-39	61	(31.6%)	10	(15.9%)		
40-49	106	(54.9%)	12	(19.0%)		
50-59	7	(3.6%)	16	(25.4%)		
60-69	14	(7.3%)	23	(36.5%)		
70-	2	(1.0%)	1	(1.6%)		
Total	193	,	63			
Median (min - max)	40 ( 20 - 70 )		50 ( 20 - 70 )			
Missing	10		7			


Fig. 5 Survival of patients treated by chemotherapy and/or radiotherapy, Radiotherapy alone (n=189) Chemoradiotherapy (n=786), Chemotherapy alone (n=78) Palliative Radiotherapy (n=11)



	Years after treatment											
_	1	2	3	4	5	6	7	8				
Radiotherapy alone	49.0%	31.9%	26.9%	21.9%	18.0%	16.1%	16.1%	16.1%				
Chemoradiotherapy	56.8%	40.0%	32.6%	26.7%	24.9%	21.1%	19.0%	19.0%				
Chemotherapy alone	32.6%	16.7%	13.7%	6.9%	6.9%	6.9%	6.9 %	6.9%				
Palliative Radiotherapy	27.3%	9.1%	-		-	-	-	-				




Fig. 6 Survival of patients treated by chemotherapy and/or radiotherapy (cStage I-IIA), Radiotherapy alone (n = 52) Chemoradiotherapy (n = 166), Chemotherapy alone (n = 10) Palliative Radiotherapy (n = 4)



	1	2	3	4	5	6	7	8
Radiotherapy alone	76.7%	62.9%	60.8%	52.2%	40.5%	38.0%	38.0%	38.0%
Chemoradiotherapy	86.4%	74.1%	64.0%	53.5%	52.7%	44.1%	38.1%	38.1%
Chemotherapy alone	80.0%	60.0%	50.0%	12.5%	12.5%	12.5%	-	-
Palliative Radiotherapy	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	-	_

Fig. 7 Survival of patients treated by chemotherapy and/or radiotherapy (cStage IIB-IVB), Radiotherapy alone (n = 116) Chemoradiotherapy (n = 584), Chemotherapy alone (n = 44) Palliative Radiotherapy (n = 7)



		Years after treatment											
-	1	2	3	4	5	6	7	- 8					
Radiotherapy alone	33.6%	13.3%	7.9%	5.4%	5.4%	5.4%	5.4%	5.4%					
Chemoradiotherapy	48.1%	30.4%	23.4%	18.9%	16.9%	14.6%	13.5%	-					
Chemotherapy alone	17.6%	7.5%	7.5%	5.0%	5.0%	5.0%	5.0%	-					
Palliative Radiotherapy	14.3%	0.0%	-	-	-	-	-	-					

# IV. Clinical results in patients treated by esophagectomy in 2005

Table 42 Tumor location

Locations	Cases (%)				
Cervical	89	(3.6%)			
Upper thotacic	298	(12.2%)			
Middle thoracic	1081	(44.2%)			
Lower thoracic	765	(31.3%)			
Abdominal	149	(6.1%)			
EG	29	(1.2%)			
EG-Junction (E=G)	22	(0.9%)			
Unknown	10	(0.4%)			
Total	2443				
Missing	13				

EG:

esophago-gastric

Table 43 Approaches to tumor resection

Approaches	Cases (%)			
Cervical approach	63	(2.6%)		
Right thoracotomy	2023	(82.6%)		
Left thoracotomy	45	(1.8%)		
Left thoracoabdominal approach	52	(2.1%)		
Laparotomy	101	(4.1%)		
Transhiatal lower esophagectomy	65	(2.7%)		
Transhiatal thoracic esophagectomy	32	(1.3%)		
Sternotomy	7	(0.3%)		
Others	53	(2.2%)		
Unknown	8	(0.3%)		
Total	2449			
Missing	7			

Table 44 Endoscopic surgery

Endoscopic surgery	Cases (%)			
None	1911	(79.0%)		
Thoracoscopy-assisted	245	(10.1%)		
Laparoscopy-assisted	97	(4.0%)		
Thoracoscopy + Laparoscopy-assisted	136	(5.6%)		
Mediastinoscopy-assisted	24	(1.0%)		
Thoracoscopy + Mediastinoscopy-assisted	1	(0.0%)		
Thoracoscopy + Laparoscopy + Mediastinoscopy-assisted	3	(0.1%)		
Others	0	(0.0%)		
Unknown	1	(0.0%)		
· Total	2418			
Missing	38			



Esophagus (2014) 11:1–20

Table 45 Fields of lymph node dissection according to the location of the tumor

<sup>\*</sup> Excluding pharynx and missing 20 cases of locations

Locations		Cevical	Ţ	Jpper	М	iddle	I	.ower	Δh	iominal		EGJ	т	otal
Locations		JO VICIN	th	oracic	the	oracic	tŀ	oracic	7100	Johnna				J
Region of lymphadenectomy	Ca	ases (%)	Ca	ses (%)	Cas	ses (%)	Ca	ses (%)	Ca	ses (%)	Ca	ises (%)	Cas	ses (%)
None	10	(11.4%)	10	(3.4%)	30	(2.8%)	28	(3.7%)	5	(3.3%)	0	(0.0%)	83	(3.4%)
С	27	(30.7%)	4	(1.4%)	3	(0.3%)	1	(0.1%)	0	(0.0%)	0	(0.0%)	35	(1.5%)
C+UM	14	(15.9%)	2	(0.7%)	2	(0.2%)	0	(0.0%)	0	(0.0%)	0	(0.0%)	18	(0.7%)
C+UM+MLM	4	(4.5%)	3	(1.0%)	12	(1.1%)	11	(1.4%)	0	(0.0%)	0	(0.0%)	30	(1.2%)
C+UM+MLM+A	21	(23.9%)	179	(61.1%)	553	(51.8%)	291	(38.3%)	7	(4.6%)	i	(0.7%)	1052	(43.7%)
C+UM+A	2	(2.3%)	1	(0.3%)	0	(0.0%)	3	(0.4%)	0	(0.0%)	0	(0.0%)	6	(0.2%)
C+MLM	0	(0.0%)	0	(0.0%)	0	(0.0%)	1	(0.1%)	0	(0.0%)	0	(0.0%)	1	(0.0%)
C+MLM+A	1	(1.1%)	0	(0.0%)	2	(0.2%)	0	(0.0%)	0	(0.0%)	0	(0.0%)	3	(0.1%)
C+A	4	(4.5%)	1	(0.3%)	4	(0.4%)	1	(0.1%)	0	(0.0%)	0	(0.0%)	10	(0.4%)
UM	0	(0.0%)	2	(0.7%)	9	(0.8%)	1	(0.1%)	0	(0.0%)	0	(0.0%)	12	(0.5%)
UM+MLM	0	(0.0%)	5	(1.7%)	13	(1.2%)	11	(1.4%)	0	(0.0%)	0	(0.0%)	29	(1.2%)
UM+MLM+A	3	(3.4%)	73	(24.9%)	378	(35.4%)	290	(38.2%)	48	(31.8%)	9	(6.0%)	801	(33.2%)
UM+A	0	(0.0%)	1	(0.3%)	3	(0.3%)	4	(0.5%)	2	(1.3%)	0	(0.0%)	10	(0.4%)
MLM	0	(0.0%)	0	(0.0%)	3	(0.3%)	6	(0.8%)	0	(0.0%)	2	(1.3%)	11	(0.5%)
MLM+A	0	(0.0%)	9	(3.1%)	39	(3.7%)	93	(12.2%)	67	(44.4%)	28	(18.5%)	236	(9.8%)
A	0	(0.0%)	2	(0.7%)	12	(1.1%)	18	(2.4%)	22	(14.6%)	10	(6.6%)	64	(2.7%)
Unknown	2	(2.3%)	1	(0.3%)	5	(0.5%)	1	(0.1%)	0	(0.0%)	0	(0.0%)	9	(0.4%)
Total	88		293		1068		760		151		50		2410	
Missing	1		5		13		5		1		1		26	

Table 47 Reconstruction route

Reconstruction route	Cases (%)				
None	41	(1.7%)			
Subcutaneous	285	(11.7%)			
Anterior mediastinal	868	(35.6%)			
Intrathoracic	369	(15.1%)			
Posterior mediastinal	828	(33.9%)			
Cervical	23	(0.9%)			
Others	18	(0.7%)			
Unknown	9	(0.4%)			
Total	2441				
Missing	15				

Table 48 Organs used for reconstruction

Organs used for reconstruction	Cases (%)			
None	50	(2.0%)		
Whole stomach	101	(4.0%)		
Gastric tube	2002	(78.5%)		
Jejunum	118	(4.6%)		
Free jejunum	37	(1.5%)		
Colon	112	(4.4%)		
Free colon	13	(0.5%)		
Skin graft	1	(0.0%)		
Others	114	(4.5%)		
Unknown	3	(0.1%)		
Total lesions	2551			
Total cases	2450			
Missing	6			



Table 55 Histological classification

Histological classification	Cas	es (%)
Not examined	2	(0.1%)
SCC	2181	(89.8%)
SCC	370	(15.2%)
Well diff.	478	(19.7%)
Moderately diff.	957	(39.4%)
Poorly diff.	376	(15.5%)
Adenocarcinoma	81	(3.3%)
Barrett's adenocarcinoma	34	(1.4%)
Adenosquamous cell carcinoma	14	(0.6%)
(Co-existing)	1 -	(0.0%)
(Mucoepidermoid carcinoma)	1	(0.0%)
Adenoid cystic carcinoma	1	(0.0%)
Basaloid carcinoma	30	(1.2%)
Undiff. carcinoma (small cell)	9	(0.4%)
Undiff. carcinoma	6	(0.2%)
Other carcinoma	2	(0.1%)
Sarcoma	1	(0.0%)
Carcinosarcoma	19	(0.8%)
Malignant melanoma	8	(0.3%)
Dysplasia	1	(0.0%)
Other	18	(0.7%)
Unkown	20	(0.8%)
Total	2429	
Missing	27	

SCC: Squamous cell carcinoma

Table 56 Depth of tumor invasion

pT-category	Cases (%)		
pTX	9	(0.4%)	
pT0	30	(1.2%)	
pTis	40	(1.6%)	
pT1a	209	(8.6%)	
pT1b	547	(22.5%)	
pT2	359	(14.8%)	
pT3	1053	(43.4%)	
pT4	158	(6.5%)	
Other	0	(0.0%)	
Unknown	23	(0.9%)	
Total	2428		
Missing	28		

Lymph node metastasis	Cases (%)			
pT0	1230	(51.4%)		
pT1	309	(12.9%)		
pT2	495	(20.7%)		
pT3	179	(7.5%)		
pT4	143	(6.0%)		
Unknown	39	(1.6%)		
Total	2395			
Missing	61			

Table 59 Numbers of the metastatic nodes

Numbers of lymph node metastasis	Case	es (%)
0	1059	(44.2%)
1-2	629	(26.3%)
3-6	455	(19.0%)
7-	252	(10.5%)
Total	2395	
Missing	61	

Table 60 Pathological findings of distant organ metastasis

Distant metastasi	Case	Cases (%)			
MX		26	(1.1%)		
M0		2319	(96.6%)		
MI		56	(2.3%)		
Total		2401			
Missing		7			

Table 61 Residual tumor

Residual tumor (R)	Case	es (%)
RX	172	(7.1%)
R0	2002	(83.0%)
R1	137	(5.7%)
R2	102	(4.2%)
Total	2413	
Missing	43	



Table 72 Causes of death

\* As of August 31, 2010


Cause of death	Cases (%)			
Death due to recurrence	817 (72.2%			
Death due to other cancer	53	(4.7%)		
Death due to other disease (rec+)	23 (2.0%			
Death due to other disease (rec-)	121 (10.7%			
Death due to other disease (rec?)	4 (0.4%			
Operative death*	32	(2.8%)		
Postoperative hospital death**	41	(3.6%)		
Unknown	41	(3.6%)		
Total of death cases	1132			
Missing	8			

#### rec: recurrence

<sup>\*</sup> Death within 30 days, \*\*Death after 30 days

Follow-up peri	iod (years)
Median (min - max)	2.75 (0.00 - 7.41 )


Fig. 8 Survival of patients treated by esophagectomy



Esophagectomy (n= 2195)


	Years after surgery									
	1 2 3 4 5 6 7 8									
Esophagectomy	81.9%	67.0%	59.2%	54.8%	50.9%	48.7%	46.7%	45.2%		

Fig. 9 Survival of patients treated by esophagectomy in relation to clinical stage (JSED TNM 9th)



	Years after surgery								
	1	2	3	4	5	6	7	8	
cStage 0	97.3%	92.7%	89.0%	86.1%	79.8%	75.9%	75.9%	75.9%	
cStage I	94.7%	91.2%	87.7%	84.4%	78.9%	75.2%	72.0%	71.0%	
cStage II	87.4%	73.8%	65.1%	59.4%	55.3%	54.6%	52.6%	50.7%	
cStage III	78.4%	57.9%	48.0%	42.9%	39.4%	36.7%	34.9%	33.5%	
cStage IVA	56.5%	29.7%	21.7%	19.1%	17.4%	16.7%	16.7%	13.3%	
cStage IVB	39.5%	19.7%	15.3%	8.8%	8.8%	8.8%	8.8%	-	


Fig. 10 Survival of patients treated by esophagectomy in relation to clinical stage (UICC TNM 6th)



		Years after surgery						
	1	2	3	4	5	6	7	8
cStage 0	87.5%	87.5%	87.5%	87.5%	87.5%	87.5%	87.5%	87.5%
cStage I	95.3%	91.0%	87.3%	83.6%	78.1%	74.5%	71.9%	71.1%
cStage IIA	87.8%	71.4%	61.9%	57.1%	53.2%	52.6%	49.5%	45.6%
cStage IIB	87.0%	72.9%	62.4%	56.9%	53.3%	51.4%	50.0%	-
cStage III	71.6%	51.2%	43.5%	38.9%	35.4%	32.7%	31.5%	29.7%
cStage IV	44.7%	33.5%	26.1%	18.6%	18.6%	18.6%	-	-
cStage IVA	70.6%	49.0%	37.3%	31.4%	29.4%	27.0%	27.0%	-
cStage IVB	74.6%	49.8%	39.2%	35.9%	35.9%	34.1%	32.8%	-




Fig. 11 Survival of patients treated by esophagectomy in relation to the depth of tumor invasion: pT (JSED TNM 9th)



	Years after surgery										
	1	2	3	4	5	6	7	8			
pTis	94.4%	88.6%	85.7%	85.7%	85.7%	80.6%	80.6%	-			
pT1a	95.1%	90.0%	87.2%	84.9%	80.7%	79.3%	76.6%	76.6%			
pT1b	93.5%	86.8%	81.5%	77.4%	71.9%	68.6%	65.5%	63.0%			
pT2	83.5%	70.6%	62.7%	56.3%	51.1%	47.9%	45.8%	-			
рТ3	78.9%	57.2%	47.0%	42.1%	39.0%	37.3%	35.9%	33.8%			
pT4	39.9%	22.5%	17.4%	15.3%	13.0%	13.0%	13.0%	-			


Fig. 12 Survival of patients treated by esophagectomy in relation to the depth of tumor invasion: pT (UICC TNM 6th)



	Years after surgery										
	1	2	3	4	5	6	7	8			
pTis	94.4%	88.6%	85.7%	85.7%	85.7%	80.6%	80.6%	_			
pT1	93.9%	87.7%	83.0%	79.5%	74.3%	71.5%	68.5%	66.7%			
pT2	83.5%	70.6%	62.7%	56.3%	51.1%	47.9%	45.8%	-			
pT3	78.9%	57.2%	47.0%	42.1%	39.0%	37.3%	35.9%	33.8%			
pT4	39.9%	22.5%	17.4%	15.3%	13.0%	13.0%	13.0%	-			




Fig. 13 Survival of patients treated by esophagectomy in relation to lymph node metastasis: pN (JSED TNM 9th)



				Years afte	er surgery			
	1	2	3	4	5	6	7	8
pN0	86.8%	77.7%	72.6%	69.1%	64.6%	62.0%	59.4%	58.7%
pN1	81.3%	67.7%	58.2%	51.7%	49.6%	47.0%	45.3%	40.2%
pN2	74.1%	54.0%	43.6%	37.9%	33.5%	31.4%	30.0%	29.1%
pN3	72.1%	49.4%	41.4%	37.4%	34.5%	34.5%	31.9%	31.9%
pN4	61.5%	31.0%	23.5%	20.1%	17.5%	16.4%	16.4%	16.4%


Fig. 14 Survival of patients treated by esophagectomy in relation to lymph node metastasis: pN (UICC TNM 6th)



		Years after surgery										
	1	2	3	4	5	6	7	8				
pN0	86.8%	77.7%	72.6%	69.1%	64.6%	62.0%	59.4%	58.7%				
pN1	74.1%	54.1%	44.6%	39.3%	36.0%	34.2%	32.7%	30.8%				




Fig. 15 Survival of patients treated by esophagectomy in relation to pathological stage (JSED TNM 9th)



	Years after surgery										
	1	2	3	4	5	6	7	8			
pStage 0	94.4%	91.2%	89.0%	87.3%	83.8%	81.7%	79.0%	79.0%			
pStage I	96.0%	91.9%	87.7%	84.5%	78.4%	74.6%	71.0%	68.5%			
pStage II	84.6%	71.1%	63.6%	58.7%	54.7%	52.7%	51.0%	51.0%			
pStage III	75.1%	54.7%	44.3%	38.7%	34.9%	33.2%	31.2%	28.2%			
pStage IVa	54.6%	27.0%	20.4%	17.8%	15.6%	14.7%	14.7%	14.7%			
pStage IVb	41.5%	19.5%	17.1%	9.8%	9.8%	9.8%	9.8%	-			


Fig. 16 Survival of patients treated by esophagectomy in relation to pathological stage (UICC TNM 6th)



	Years after surgery									
	1	2	3	4	5	6	7	8		
pStage 0	91.3%	87.9%	84.5%	84.5%	80.8%	80.8%	80.8%	80.8%		
pStage I	95.6%	92.0%	88.8%	85.9%	80.7%	77.2%	73.7%	71.9%		
pStage IIA	83.7%	68.9%	62.0%	58.0%	53.8%	51.9%	50.1%	50.1%		
pStage IIB	83.9%	70.8%	61.5%	54.4%	49.8%	47.8%	45.9%	45.9%		
pStage III	69.2%	46.2%	36.5%	32.0%	29.1%	27.6%	26.3%	23.4%		
pStage IV	38.4%	17.1%	14.9%	8.5%	8.5%	8.5%	8.5%	-		




Fig. 17 Survival of patients treated by esophagectomy in relation to number of metastatic node



	Years after surgery										
	1	2	3	4	5	6	7	8			
0	91.0%	83.7%	78.4%	75.1%	70.3%	67.7%	65.1%	64.0%			
1-2	83.7%	68.5%	60.9%	54.9%	51.3%	48.9%	46.6%	44.5%			
3-6	73.2%	48.9%	36.6%	30.9%	28.4%	25.5%	24.2%	22.7%			
7-	59.2%	29.6%	20.8%	16.3%	12.6%	12.6%	12.6%	12.6%			

Fig. 18 Survival of patients treated by esophagectomy in relation to residual tumor



	Years after surgery										
	1	2	3	4	5	6	7	8			
R0	85.8%	72.7%	64.2%	59.1%	56.1%	53.8%	49.0%	46.8%			
R1	58.1%	34.4%	24.6%	22.3%	17.2%	15.4%	14.3%	14.3%			
R2	43.5%	14.2%	7.1%	6.2%	5.3%	5.3%	4.4%	-			



## SPECIAL ARTICLE

## Comprehensive Registry of Esophageal Cancer in Japan, 2006

Yuji Tachimori · Soji Ozawa · Mitsuhiro Fujishiro · Hisahiro Matsubara · Hodaka Numasaki · Tsuneo Oyama · Masayuki Shinoda · Yasushi Toh · Harushi Udagawa · Takashi Uno

Published online: 14 September 2013

© The Japan Esophageal Society and Springer Japan 2013

#### **Preface**

We deeply appreciate the great contributions of many physicians in the registry of esophageal cancer cases. The Comprehensive Registry of Esophageal Cancer in Japan, 2006, was published here, despite some delay. The registry complies with the Act for the Protection of Personal Information. The encryption with a HASH function is used for "anonymity in an unlinkable fashion".

These data were first made available on July 1, 2013, as the Comprehensive Registry of Esophageal Cancer in Japan, 2006. Not all the pages are reprinted here; however, the original table and figure numbers have been maintained.

The authors were members of the Registration Committee for Esophageal Cancer, the Japan Esophageal Society, and made great contributions to the preparation of this material.

## Y. Tachimori (🖂)

Esophageal Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan e-mail: ytachimo@ncc.go.jp

## S. Ozawa

Department of Gastroenterological Surgery, Tokai University School of Medicine, Isehara, Japan

## M. Fujishiro

Department of Endoscopy and Endoscopic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

## H. Matsubara

Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan

## H. Numasaki

Department of Medical Physics and Engineering, Osaka University Graduate School of Medicine, Osaka, Japan

We briefly summarized the Comprehensive Registry of Esophageal Cancer in Japan, 2006. Japanese Classification of Esophageal Cancer 9th and UICC TNM Classification 6th were used for cancer staging according to the subjected year. A total of 4994 cases were registered from 239 institutions in Japan. Tumor locations were cervical: 4.2 %, upper thoracic: 13.4 %, middle thoracic: 48.7 %, lower thoracic: 26.0 % and EG junction: 6.7 %. Superficial carcinomas (Tis, T1a, T1b) were 35.9 %. As for the histologic type of biopsy specimens. squamous cell carcinoma and adenocarcinoma accounted for 90.8 and 3.9 %, respectively. Regarding clinical results, the 5-year survival rates of patients treated using endoscopic mucosal resection, concurrent chemoradiotherapy, radiotherapy alone, chemotherapy alone, or esophagectomy were 84.5, 25.8, 22.0, 3.0, and 48.0 %, respectively. Esophagectomy was performed in 2545 cases. Concerning the approach used for esophagectomy, 15.4 % of the cases were

## T. Oyama

Department of Gastroenterology, Saku General Hospital, Nagano, Japan

## M. Shinoda

Department of Thoracic Surgery, Aichi Cancer Center Hospital, Aichi, Japan

## Y. Toh

Department of Gastroenterological Surgery, National Kyushu Cancer Center, Fukuoka, Japan

## H. Udagawa

Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan

## T. Uno

Department of Radiology, Graduate School of Medicine, Chiba University, Chiba, Japan



thoracoscopically. The operative mortality (within 30 days after surgery) was  $1.0\,\%$  and the hospital mortality was  $2.1\,\%$ .

We hope that this Comprehensive Registry of Esophageal Cancer in Japan for 2006 will help to improve all aspects of the diagnosis and treatment of esophageal cancer in Japan.

## **Contents**

- I. Clinical factors of esophageal cancer patients treated in 2006
  - 1. Institution-registered cases in 2006
  - 2. Patient background

Table 1 Age and gender

Table 11 Types of primary treatment

**Table 12 Tumor location** 

Table 15 Histologic types of biopsy specimens

Table 16 Depth of tumor invasion, cT (UICC

TNM 6th)

Table 17 Lymph node metastasis, cN (UICC

TNM 6th)

Table 18 Distant metastasis, cM (UICC TNM

6th)

Table 20 Clinical stage (UICC TNM 6th)

- II. Clinical results of patients treated with endoscopy in 2006
  - Table 22 Treatment details in patients receiving endoscopy

Table 26 Complications of EMR/ESD

Table 30 Depth of tumor invasion of EMR/ESD specimens

Figure 3 Survival of patients treated by EMR/ESD in relation to the pathological depth of tumor invasion (pT)

Figure 4 Survival of patients treated by EMR/ESD in relation to the lymphatic or venous invasion

- III. Clinical results in patients treated with chemotherapy and/or radiotherapy in 2006
  - Table 33 Dose of irradiation (non-surgically treated cases)

Table 34 Dose of irradiation (surgically treated cases)

Figure 5 Survival of patients treated by chemotherapy and/or radiotherapy

Figure 6 Survival of patients treated by chemotherapy and/or radiotherapy (cStage I-IIA)

Figure 7 Survival of patients treated by chemotherapy and/or radiotherapy (cStage IIB-IVB)

- IV. Clinical results in patients treated with esophagectomy in 2006
  - **Table 42 Tumor location**

Table 43 Approaches to tumor resection

**Table 44 Endoscopic surgery** 

Table 45 Fields of lymph node dissection according to the location of the tumor

**Table 47 Reconstruction route** 

Table 48 Organs used for reconstruction

Table 55 Histological classification

Table 56 Depth of tumor invasion

Table 58 Pathological grading of lymph node metastasis

Table 59 Numbers of the metastatic nodes

Table 60 Pathological findings of distant organ metastasis

Table 61 Residual tumor

Table 72 Causes of death

Figure 8 Survival of patients treated by esophagectomy

Figure 9 Survival of patients treated by esophagectomy in relation to clinical stage (JSED TNM 9th)

Figure 10 Survival of patients treated by esophagectomy in relation to clinical stage (UICC TNM 6th)

Figure 11 Survival of patients treated by esophagectomy in relation to the depth of tumor invasion: pT (JSED TNM 9th)

Figure 12 Survival of patients treated by esophagectomy in relation to the depth of tumor invasion: pT (UICC TNM 6th)

Figure 13 Survival of patients treated by esophagectomy in relation to lymph node metastasis: pN (JSED TNM 9th)

Figure 14 Survival of patients treated by esophagectomy in relation to lymph node metastasis: pN (UICC TNM 6th)

Figure 15 Survival of patients treated by esophagectomy in relation to pathological stage (JSED TNM 9th)

Figure 16 Survival of patients treated by esophagectomy in relation to pathological stage (UICC TNM 6th)

Figure 17 Survival of patients treated by esophagectomy in relation to number of metastatic node

Figure 18 Survival of patients treated by esophagectomy in relation to residual tumor: R

## I. Clinical factors of esophageal cancer patients treated in 2006

Institution-registered cases in 2006

#### Institution

Aichi Cancer Center Aizawa Hospital

Akita University Hospital Arao Municipal Hospital

Asahikawa Medical College Hospital

Chiba Cancer Center Chiba Medical Center

Chiba Prefecture Sawara Hospital

Chiba University Hospital

Chibaken Saiseikai Narashino Hospital Dokkyo Medical University Hospital

Foundation for Detection of Early Gastric Carcinoma

Fuchu Hospital

Fujioka General Hospital Fujisawa Shounandai Hospital Fujita Health University Fukui Red Cross Hospital Fukui University Hospital

Fukuoka Saiseikai General Hospital Fukuoka University Hospital

Gifu Prefectural General Medical Center

Gifu University Hospital

Gunma Central General Hospital Gunma Prefectural Cancer Center Gunma University Hospital Hakodate Goryokaku Hospital Hakodate National Hospital

Hamamatsu University School of Medicine, University Hospital

Hannan Chuo Hospital

Health Insurance Naruto Hospital

Hiratsuka City Hospital Hiratsuka Kyosai Hospital Hiroshima City Asa Hospital

Hiroshima University Research Institute for Radiation Biology

Medicine

Hitachi General Hospital

Hokkaido Kin-Ikyo Chuo Hospital

Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital

Hokkaido University Hospital Hyogo College of Medicine Ibaraki Prefectural Central Hospital

Imazu Surgical Clinic Inazawa City Hospital

International University of Health and Welfare Mita Hospital

Ishikawa Prefectural Central Hospital

#### continued

## Institution

Ishinomaki Red Cross Hospital

Iwakuni Medical Center

Iwate Medical University Hospital Iwate Prefectural Chubu Hospital Japanese Red Cross Shizuoka Hospital

Juntendo University Hospital

Juntendo University Shizuoka Hospital

Junwakai Memorial Hospital

Kagawa Prefectural Central Hospital Kagawa Rosai Hospital

Kagawa University Hospital
Kagoshima Kenritsu Satsunan Hospital

Kagoshima University Hospital Kanazawa Medical University Hospital

Kanazawa University Hospital

Kansai Medical University Hirakata Hospital

Kansai Rosai Hospital Kasamatsu Hospital

Kashiwa Kousei General Hospital Kawakita General Hospital Kawasaki Medical School Hospital Kawasaki Municipal Hospital Kawasaki Municipal Ida Hospital

Keio University Hospital
Keiyukai Sapporo Hospital
Kikuna Memorial Hospital
Kinki Central Hospital
Kinki University Hospital
Kinki University Sakai Hospital
Kiryu Kosei General Hospital
Kishiwada City Hospital

Kitakyushu Municipal Medical Center

Kitasato University Hospital

Kitasato University Kitasato Institute Medical Center Hospital

Kobe City Medical Center General Hospital

Kochi University Hospital Kumamoto University Hospital Kurashiki Central Hospital

Kurume Daiichi Social Insurance Hospital

Kurume University Hospital Kuwana West Medical Center Kyorin University Hospital Kyoto University Hospital

Kyushu Central Hospital of the Mutual Aid Association of Public

School Teachers

Kyushu University Beppu Hospital Kyushu University Hospital

Matsuda Hospital

Matsushita Memorial Hospital